ABSTRACT
BACKGROUND In older adults, elevated pulse pressure predicts cognitive decline, irrespective of overall blood pressure. It is proposed to compromise cerebrovascular integrity, potentially leading to brain damage, though the underlying mechanisms remain unclear. We hypothesized that pulse pressure affects cognition by disrupting white matter microstructure, and that it does so independently of other cardiovascular risk factors.
METHODS Indices of pulse pressure, overall blood pressure and heart rate variability were estimated in a cross-sectional population-based cohort (n=708, aged 18-88 years). An indicator of white matter microstructure was derived from diffusion-weighted imaging, termed the “peak width of skeletonised mean diffusivity” (PSMD). Cognitive function was assessed using measures of processing speed.
RESULTS In robust multiple linear regressions, pulse pressure significantly predicted PSMD. We also found that PSMD significantly predicted processing speed. Thus higher pulse pressure was associated with greater white matter disruption, and greater white matter disruption was associated with slower processing abilities.This motivated testing whether PSMD mediates the effects of pulse pressure on processing speed. We tested this using a number of structural equation models. PSMD significantly and substantially mediated the effect of pulse pressure on processing speed, over and above age and other cardiovascular factors. We then expanded the model to show that vascular-related changes in processing speed in turn drive changes in higher cognitive functions.
CONCLUSIONS High pulse pressure disrupts microstructural integrity of white matter in the brain, leading to slower processing speed. We propose that better manament of pulse pressure could help to preserve white matter integrity and reduce cognitive decline in later life.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Cam-CAN was supported by the Biotechnology and Biological Sciences Research Council Grant BB/H008217/1. D.L.O.K. was supported by a Doctoral Training Programme studentship awarded by the Biotechnology and Biological Sciences Research Council (BBSRC BB/M011194/1) K.A.T. was supported by Fellowship awards from the Guarantors of Brain (G101149) and Alzheimers Society, UK (grant number 602). R.N.A.H. was supported by the UK Medical Research Council (SUAG/046 G101400) and the European Unions Horizon 2020 research and innovation programme (LifeBrain, Grant Agreement No. 732592). . J.B.R. is funded by the Welcome Trust (220258), the Cambridge University Centre for Frontotemporal Dementia, the Medical Research Council (MC_UU_00030/14; MR/T033371/1); the National Institute for Health Research Cambridge Biomedical Research Centre (NIHR203312: BRC-1215-20014) and the Holt Fellowship. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Cambridgeshire 2 (now East of England, Cambridge Central) Research Ethics Committee (reference: 10/H0308/50).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos